Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
about
Targeting EZH2 in cancerEZH2 in normal hematopoiesis and hematological malignanciesThe epigenetic basis of diffuse large B-cell lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewEpigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?Targeting epigenetic regulations in cancerTargeting EZH2 and PRC2 dependence as novel anticancer therapy.Targeting EZH2 for cancer therapy: progress and perspective.EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling.Epigenetic Medicinal Chemistry.Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.EZH2 inhibitors: a patent review (2014-2016).Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatmentEPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.Development and Use of Assay Conditions Suited to Screening for and Profiling of SET-Domain-Targeted Inhibitors of the MLL/SET1 Family of Lysine Methyltransferases.Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.Select human cancer mutants of NRMT1 alter its catalytic activity and decrease N-terminal trimethylation.Small molecule inhibitors of EZH2: the emerging translational landscape.Cancer epigenetics: Moving forward.
P2860
Q26769027-2FACF37C-55D2-449D-9F34-D8ACAE12A615Q26779821-383EEAF4-6E65-4033-9A2D-410B27041453Q26852288-53F0F7FE-F560-4704-97F9-638655043F00Q27304386-6089BBF6-B926-41D3-8506-3DA16C87E4A9Q28076548-05D939B2-B261-40DB-92AC-33506FA04E42Q36398751-F24C1217-BB8F-458F-8708-4F217C14C0E6Q36445523-CDE0DC82-D349-4F10-8D2A-9E9B045EFF02Q37204063-42819A32-4CF8-4CA2-A597-F872F3A5A735Q37520284-29FF00D2-0584-4283-97E0-D524E4EC34FFQ38434114-D8A6BE59-59E9-4E01-9719-9319654518FAQ38641649-8A0F9CD8-2655-4729-9B2E-615CD0CC36CBQ38707876-E2AE1912-F28A-4A5B-A6C6-053711E650D2Q38844652-BB96D9F8-C90E-4C7F-A550-66B5C482D3ECQ38906194-2E084D76-3E66-4E30-B277-7C8FD85CC9BDQ40014635-D895EA25-9D3C-4F83-A8C9-3777E6BEA971Q40753278-5E34C769-B2C7-48F0-98B2-85DC8D62E72EQ41449642-3AF5D5C0-7962-4263-A3F0-D488B6BC87D9Q42321107-23201A49-386A-4379-BE83-2807B01A216EQ46095043-5B420C54-AE10-4B56-915E-AB35EC2D0DA2Q50005505-A8EA0B43-1E92-4EEB-A7C2-A54A133B7BF2Q50324483-5A0A96D3-320E-49BD-832F-20B432C403CFQ50971966-8124BBDF-DC6F-46E0-B24B-436DA4284486Q53654363-AC1CB5E4-7B82-4B1B-A8FD-9BA9DE3818E4Q55177661-5981D346-7A21-46D2-8597-A36A44B43FD1
P2860
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@ast
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@en
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@nl
type
label
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@ast
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@en
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@nl
prefLabel
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@ast
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@en
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@nl
P2093
P2860
P1433
P1476
Synergistic Anti-Tumor Activit ...... l Center Non-Hodgkin Lymphomas
@en
P2093
Alejandra Raimondi
Bruce A Littlefield
Christine R Klaus
Dorothy Iwanowicz
Heike Keilhack
Jesse J Smith
Kevin W Kuntz
L Danielle Johnston
Margaret Porter-Scott
Mikel P Moyer
P2860
P304
P356
10.1371/JOURNAL.PONE.0111840
P407
P577
2014-12-10T00:00:00Z